Detalles de la búsqueda
1.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Haematologica
; 109(2): 543-552, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37560813
2.
Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis.
Eur J Haematol
; 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38661269
3.
Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.
Acta Oncol
; 63: 267-272, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38709114
4.
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020.
Br J Haematol
; 201(1): 64-74, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36513500
5.
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
Br J Haematol
; 200(3): 306-314, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36261137
6.
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Br J Haematol
; 202(4): 776-784, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37386877
7.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Br J Haematol
; 202(4): 749-759, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36257914
8.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Haematologica
; 108(1): 110-121, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770532
9.
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hematol Oncol
; 41(5): 848-857, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37496298
10.
Participatory action research intervention for improving sleep in inpatients with cancer.
J Clin Nurs
; 32(7-8): 1218-1229, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35289008
11.
Mortality among patients with low-grade follicular lymphoma: A binational retrospective analysis.
Cancer
; 128(13): 2474-2482, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35417924
12.
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Br J Haematol
; 196(3): 589-598, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34632572
13.
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Blood
; 135(13): 996-1007, 2020 03 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31977002
14.
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
Histopathology
; 81(6): 826-840, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36109172
15.
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.
Hematol Oncol
; 40(4): 505-517, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35488888
16.
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Invest New Drugs
; 39(4): 1028-1035, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33523334
17.
Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
Hematol Oncol
; 39(3): 419-422, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33369766
18.
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
Ann Hematol
; 100(4): 1023-1029, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32367180
19.
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol
; 17(11): 1295-1310, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33528286
20.
Precision medicine in follicular lymphoma: Focus on predictive biomarkers.
Hematol Oncol
; 38(5): 625-639, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700331